|
Market Closed -
Nasdaq
16:00:00 2026-11-04 EST
|
5-day change | 1st Jan Change | ||
| 8.240 USD | -3.85% |
|
-1.55% | +5.64% |
| 11-04 | BioCryst Pharmaceuticals, Inc., Q3 2026 Earnings Call, Nov 04, 2026 | |
| 11-04 | Wedbush Adjusts BioCryst Pharmaceuticals PT to $17 From $18, Maintains Outperform Rating | MT |
| Market Cap | 2.11B 1.88B 1.72B 1.57B 2.95B 199B 3.01B 20.61B 8.26B 106B 7.92B 7.75B 334B | P/E 2026 * |
-3.57x | P/E 2027 * | 12.2x |
|---|---|---|---|---|---|
| Enterprise Value | 2.23B 1.99B 1.82B 1.65B 3.11B 211B 3.18B 21.76B 8.72B 111B 8.36B 8.19B 353B | EV / Sales 2026 * |
3.14x | EV / Sales 2027 * | 2.72x |
| Free-Float |
94.69% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| BCRX | Delayed | |
CBOE
| BCRX | Real-time | |
|
Tradegate
| BO1 | Real-time | |
|
Boerse Muenchen
| BO1 | Real-time | |
|
Mexican S.E.
| BCRX * | End-of-day quote | |
|
Deutsche Boerse AG
| BO1 | Delayed | |
|
Börse Stuttgart
| BO1 | Delayed | |
|
Berne S.E.
| BO1 | End-of-day quote |
Last Transcript: BioCryst Pharmaceuticals, Inc.
| 1 day | -3.85% | ||
| 1 week | -1.55% | ||
| Current month | -2.72% | ||
| 1 month | +0.86% | ||
| 3 months | -8.65% | ||
| 6 months | -10.43% | ||
| Current year | +5.64% |
| 1 week | 8.1 |  | 8.86 |
| 1 month | 7.52 | | 8.86 |
| Current year | 6.23 | | 11.22 |
| 1 year | 6.23 | | 11.22 |
| 3 years | 4.03 | | 11.31 |
| 5 years | 4.03 | | 19.99 |
| 10 years | 1.38 | | 19.99 |
| Manager | Title | Age | Since |
|---|---|---|---|
Charles Gayer
CEO | Chief Executive Officer | 55 | 2025-12-31 |
Babar Ghias
DFI | Director of Finance/CFO | 47 | 2025-07-06 |
Sandeep Menon
CTO | Chief Tech/Sci/R&D Officer | 51 | 2026-04-05 |
| Director | Title | Age | Since |
|---|---|---|---|
Jon Stonehouse
BRD | Director/Board Member | 65 | 2006-12-31 |
Theresa Heggie
BRD | Director/Board Member | 65 | 2018-12-02 |
Charles Gayer
BRD | Director/Board Member | 55 | 2025-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/31/26 | Free | Director | 644 | 0.0003% | ||
| 8/31/26 | Free | Director | 644 | 0.0003% | ||
| 8/31/26 | Free | Director | 1,288 | 0.0005% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.85% | -1.55% | +21.89% | +36.42% | 2.19B | |
| +10.00% | +4.50% | +58.63% | +71.20% | 60.57B | |
| +1.44% | +5.05% | +22.52% | +101.03% | 55.51B | |
| +3.32% | +2.31% | +11.04% | +75.04% | 55.22B | |
| +0.46% | -5.47% | +25.04% | +33.77% | 43.27B | |
| +2.82% | +5.82% | +240.96% | +801.17% | 41.63B | |
| +6.42% | +1.18% | +22.18% | +105.56% | 40.36B | |
| -3.79% | -7.50% | +89.46% | +77.13% | 33.29B | |
| +5.32% | +5.37% | +19.12% | +52.98% | 32.27B | |
| +5.32% | +13.43% | -39.82% | +342.66% | 22.91B | |
| Average | +2.75% | +5.95% | +47.10% | +169.70% | 38.72B | |
| Weighted average by Cap. | +3.68% | +4.85% | +52.04% | +168.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 710M 633M 580M 527M 991M 67.11B 1.01B 6.94B 2.78B 35.52B 2.67B 2.61B 113B | 736M 656M 602M 547M 1.03B 69.6B 1.05B 7.19B 2.88B 36.84B 2.76B 2.71B 117B |
| Net income | -582M -518M -475M -432M -812M -54.99B -831M -5.68B -2.28B -29.1B -2.18B -2.14B -92.19B | 175M 156M 143M 130M 244M 16.55B 250M 1.71B 686M 8.76B 657M 643M 27.75B |
| Net Debt | 118M 105M 96.36M 87.57M 165M 11.14B 168M 1.15B 462M 5.9B 443M 433M 18.68B | -109M -96.69M -88.67M -80.58M -151M -10.25B -155M -1.06B -425M -5.43B -407M -399M -17.19B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-04 | US$8.240 | -3.85% | 10,225,512 |
| 26-11-03 | US$8.570 | +3.94% | 6,532,990 |
| 26-11-02 | US$8.245 | -2.66% | 4,090,292 |
| 26-10-30 | US$8.470 | -0.59% | 3,527,215 |
| 26-10-29 | US$8.520 | +1.79% | 4,519,169 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BCRX Stock
Select your edition
All financial news and data tailored to specific country editions
